BIO-acetoxime

Research use only, not for human use.

BIO-acetoxime is a potent dual GSK3α/β inhibitor with IC50 of 10 nM, >240-fold selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B.

BIO-Acetoxime is a potent and selective GSK-3a/b inhibitor that reduces invasiveness of gliomas and extends animal survival in intracranial glioma models. Also, BIO-Acetoxime induces Wnt signaling and inhibits CD8+ T cell effector differentiation. BIO-acetoxime is a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus. BIO-Acetoxime protects cells from varicella infection. BIO-acetoxime may suppress viral gene expression and protect oral epithelial cells from HSV-1 infection.

BIO-acetoxime (BIA; Compound 13) is a potent and selective GSK-3α/β inhibitor, with IC50s of both 10 nM. BIO-acetoxime (BIA) shows weak effect on CDK5/p35 (IC50, 2.4 μM), CDK2/cyclin A (IC50, 4.3 μM), and CDK1/cyclin B (IC50, 63 μM). BIO-acetoxime (BIA) (5 μM and 10 μM) increases the viability of HSV-1-infected cells but shows little effect on morphology and viability of mockin-fected cells. Moreover, BIO-acetoxime (BIA) (0.625, 1.25, 2.5, 5, and 10 μM) significantly reduces the release of HSV-1 particles in OC3 cells, with an EC50 of 0.68 ± 0.28 μM. BIO-acetoxime (BIA) inhibits the expression of HSV-1 genes, and may not affect the nuclear targeting of HSV-1 capsids. In addition, delayed addition of BIO-acetoxime (BIA) also inhibits HSV-1 infection.

BIO-acetoxime (BIA) shows anticonvulsant effects in the focal pilocarpine rat model at 0.5 mg/kg, and in 6-Hz fully kindled FVB/N mice at 0.5, 2.5, and 5 mg/kg via i.p. administration.

BIO-acetoxime | 6-Bromoindirubin-3′-acetoxime, BIA

GPCR/G Protein

Hedgehog (Hh)

GSK-3α| GSK-3β

Inflammation/Immunology

——

667463-85-6

398.21

C18H12BrN3O3

>98% (HPLC)

DMSO : 20.83 mg/mL. 52.31 mM; H2O : < 0.1 mg/mL

CC(=O)O\N=C1C2=CC=CC=C2NC/1=C1\C(=O)NC2=C1C=CC(Br)=C2

(2Z,3E)-3-(acetoxyimino)-6'-bromo-[2,3'-biindolinylidene]-2'-one

(-20℃)

With Ice Pack

≥ 2 years